Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations

JAK2V617F is the most common mutation in patients with BCR-ABL negative myeloproliferative neoplasms (MPNs). The eradication of JAK2V617F hematopoietic stem cells (HSCs) is critical for achieving molecular remissions and cure. We investigate the distinct effects of two therapies, ruxolitinib (JAK1/2...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia Vol. 34; no. 4; pp. 1075 - 1089
Main Authors: Austin, Rebecca J., Straube, Jasmin, Bruedigam, Claudia, Pali, Gabor, Jacquelin, Sebastien, Vu, Therese, Green, Joanne, Gräsel, Julius, Lansink, Lianne, Cooper, Leanne, Lee, Shin-Jye, Chen, Nien-Tsu, Lee, Chung-Wei, Haque, Ashraful, Heidel, Florian H., D’Andrea, Richard, Hill, Geoff R., Mullally, Ann, Milsom, Michael D., Bywater, Megan, Lane, Steven W.
Format: Journal Article
Language:English
Published: London Nature Publishing Group UK 01-04-2020
Nature Publishing Group
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first